References
liver stiffness, PCOS,, weight loss, polycystic ovary syndrome
ADVERSE EVENT, INSULIN RESISTANCE, ADVERSE EVENT
Flow diagram of this randomized, controlled, open-label trial. CRD, calorie-restricted diet. RCT, randomized controlled trial.Time-to-event analysis of achieving 7% weight loss of initial body weight in the two groups. CRD, calorie-restricted diet; HR, hazard ratio.The change in VAT area from baseline to reach 7% weight loss of initial body weight in the intention-to-treat population. CRD, calorie-restricted diet; LS, least-squares; VAT, visceral adipose tissue.Baseline characteristics of overweight/obese patients with PCOS.The data are presented as the mean (95% CI). AD, androstenedione; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CAP, controlled attenuation parameter; Cr, Creatinine; CRD, calorie-restricted diet; DBP, diastolic blood pressure; DHEAS, dehydroepiandrosterone sulfate; FAI, free androgen index; FINS, fasting insulin; FPG, fasting plasma glucose; FSH, follicle-stimulating hormone; FT, free testosterone; HbA1c, glycosylated hemoglobin A1c; HDL-c, high- density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; LDL-c, low-density lipoprotein cholesterol; LH, luteinizing hormone; LSM, liver stiffness measurement; PCOS, polycystic ovary syndrome; PINS, postprandial insulin; PPG, postprandial plasma glucose; PRL, pituitary prolactin; SAT, subcutaneous adipose tissue; SBP, systolic blood pressure; SHBG, sex hormone-binding globulin; SUA, serum uric acid; TC, total cholesterol; TG, triglyceride; TT, total testosterone; VAT, visceral adipose tissue; WC, waist circumference.Secondary efficacy endpoints.Mean differences between the two treatment groups were presented as least-squares mean change with 95% CI. AD, androstenedione; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CAP, controlled attenuation parameter; Cr, creatinine; CRD, calorie-restricted diet; DBP, diastolic blood pressure; DHEAS, dehydroepiandrosterone sulfate; FAI, free androgen index; FINS, fasting insulin; FPG, fasting plasma glucose; FSH, follicle-stimulating hormone; FT, free testosterone; HbA1c, glycosylated hemoglobin A1c; HDL-c, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; LDL-c, low-density lipoprotein cholesterol; LH, luteinizing hormone; LS, least-squares; LSM, liver stiffness measurement; PCOS, polycystic ovary syndrome; PINS, postprandial insulin; PPG, postprandial plasma glucose; PRL, pituitary prolactin; SAT, subcutaneous adipose tissue; SBP, systolic blood pressure; SHBG, sex hormone-binding globulin; SUA, serum uric acid; TC, total Cholesterol; TG, triglyceride; TT, total testosterone; WC, waist circumference.Adverse events and safety data during the treatment in two groups.CRD, calorie-restricted diet; GI, gastrointestinal; TEAE treatment-emergent adverse event.